Trending

Stock to watch: Shilpa Medicare stock in focus after receiving CEP from EDQM for diabetes drug

Image

Shares of Shilpa Medicare will be highlighted as its subsidiary, Shilpa Pharma Lifesciences, obtained a certificate of suitability from European regulators for Desmopressin. This API is used in diabetes treatment. The certification marks a milestone for the company. Shilpa Medicare's stock has increased notably in 2024 despite recent declines.

You Might Also Like...

Sign Up for Our Newsletter

Subscribe now to get notified about exclusive offers
from The .... every week!